Joint Analysis of CCAAT/Enhancer-Binding Protein Beta and Interleukin 1 Beta in the Treatment and Prognosis of Diffuse Large B-Cell Lymphoma.

Objective: The purpose of this study is to investigate the correlation between elevated levels of CCAAT/enhancer-binding protein beta () gene expression and unfavorable outcomes in diffuse large B-cell lymphoma (DLBCL). The goal is to elucidate potential therapeutic targets associated with this relationship.

Methods: Differential expression and survival analyses were conducted using data from the Gene Expression Omnibus (GEO) database. The functions of in DLBCL cells were investigated through cell culture, RNA extraction, quantitative real-time polymerase chain reaction (qRT-PCR), and Western blot. In addition, a weighted gene co-expression network analysis (WGCNA) was performed to pinpoint gene modules associated with . Furthermore, experimental validation was carried out to explore the interaction between and interleukin 1 beta ().

Results: High levels of expression are prominently observed in DLBCL, with its overabundance significantly linked to the diagnosis of DLBCL. Survival analysis reveals that patients exhibiting elevated expression tend to experience a poorer prognosis. Further validation confirmed 's role in promoting DLBCL cell proliferation and cell cycle progression. WGCNA identified -related gene modules, with identified as a potential regulatory gene of . The presence of high levels of has been correlated with an unfavorable prognosis in individuals diagnosed with DLBCL. Experiments demonstrate that promotes DLBCL cell proliferation through .

Conclusions: This study reveals the significant roles of and in DLBCL, providing new theoretical foundations and potential molecular targets for the treatment and prognosis of DLBCL.